Cycle Pharmaceuticals Ltd.   Report issue

For profit Phase 1
Founded: Cambridge United Kingdom (2012)
Status: No NME R&D (2012)

Organization Overview

First Clinical Trial
2015
NCT02750709
First Marketed Drug
2012
quinidine
First NDA Approval
None
Last Known Activity
2019

Timeline

NOW
  • Now

Alternative names

CYCLE | Cycle Pharmaceuticals Ltd. | CYCLE PHARMS LTD

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Malnutrition (Phase 1)

Mental Disorders (Phase 1)

Porphyria, Acute Intermittent (Phase 1)

Porphyrias (Phase 1)

Psychomotor Agitation (Phase 1)

Psychotic Disorders (Phase 1)

Tyrosinemias (Phase 1)

Vomiting (Phase 1)

Overview

  • Highest Phase: Phase 1
  • # of Trials: 6
  • # of Trial APIs: 3